eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort

References

• Van Rompay KKA, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52(9):3144–3160.
   PubMed Web of Science ®Google Scholar
• Ascher SB, Scherzer R, Estrella MM, et al. Association of urinary biomarkers of kidney injury with estimated GFR decline in HIV-infected individuals following tenofovir disoproxil fumarate initiation. Clin J Am Soc Nephrol. 2018;13(9):1321–1329.
   Web of Science ®Google Scholar
• Jotwani V, Scherzer R, Estrella MM, et al. Brief report: Cumulative tenofovir disoproxil fumarate exposure is associated with biomarkers of tubular injury and fibrosis in HIV-infected men. J Acquir Immune Defic Syndr. 2016;73(2):177–181.
   Web of Science ®Google Scholar
• Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. Aids. 2012;26(7):867–875.
   PubMed Web of Science ®Google Scholar
• Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010;53(1):62–69.
   Web of Science ®Google Scholar
• Quesada PR, Esteban LL, García JR, et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm. 2015;37(5):865–872.
   PubMed Web of Science ®Google Scholar
• Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67(1):52–58.
   PubMedGoogle Scholar
• Podany AT, Bares SH, Havens J, et al. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. Aids. 2018;32(6):761–765.
   PubMed Web of Science ®Google Scholar
• Surial B, Cavassini M, Calmy A, Swiss HIV Cohort Study, et al. Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. BMC Infect Dis. 2019;19(1):834.
   Web of Science ®Google Scholar
• Li X, Brown TT, Ho KS, Witt MD, Phair J, Jacobson LP. Recent trends and effectiveness of antiretroviral regimens among men who have sex with men living with HIV in the United States: The Multicenter AIDS Cohort Study (MACS) 2008–2017. Open Forum Infect Dis. 2019;6(9):ofz333–ofz.
   Web of Science ®Google Scholar
• Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. Aids. 2019;33(9):1455–1465.
   PubMed Web of Science ®Google Scholar
• Orkin C, Molina J-M, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5:e23–e34.
   PubMed Web of Science ®Google Scholar
• Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347–e56.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Haas B, Segal-Maurer S, et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment. AIDS Res Hum Retrovirus. 2018;34(4):337–342.
   PubMed Web of Science ®Google Scholar
• Orkin C, DeJesus E, Ramgopal M, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017;4(5):e195–e204.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3(4):e158-65–e165.
   Web of Science ®Google Scholar
• Baxi SM, Scherzer R, Greenblatt RM, et al. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. Aids. 2016;30(4):609–618.
   PubMed Web of Science ®Google Scholar
• Turner D, Drak D, O’Connor CC, Templeton DJ, Gracey DM. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service. AIDS Res Ther. 2019;16(1):40.
   Web of Science ®Google Scholar
• Rieke A, Jessen H, Pauli R, Waizmann M, Heuchel T, Postel N., editors. Real-world effects of treatment with emtricitabine/tenofovir alafenamide versus emtricitabine/tenofovir disoproxil fumarate-based regimens in people living with HIV in a clinical cohort in Germany. HIV Glasgow; 2018 October 28–31; Glasgow, UK.
   Google Scholar
• Mothobi NZ, Masters J, Marriott DJ. Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient. Ther Adv Infect Dis. 2018;5(5):91–95.
   Web of Science ®Google Scholar
• Walti LN, Steinrucken J, Rauch A, Wandeler G. Tenofovir alafenamide in multimorbid HIV-infected patients with prior tenofovir-associated renal toxicity. Open Forum Infect Dis. 2018;5(11):ofy275.
   Web of Science ®Google Scholar
• Gallagher A, Quan D, Gracey DM. Improvement in renal function and resolution of proteinuria in an HIV-infected patient switched from tenofovir disoproxil fumarate to tenofovir alafenamide. Intern Med J. 2017;47(7):826–827.
   Web of Science ®Google Scholar
• Mikula JM, Manion MM, Maldarelli F, et al. Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy. Antivir Ther. 2016;21(6):553–558.
   Web of Science ®Google Scholar
• Karris MY. Short communication: Resolution of tenofovir disoproxil fumarate induced fanconi syndrome with switch to tenofovir alafenamide fumarate in a HIV-1 and hepatitis B coinfected patient. AIDS Res Hum Retrovirus. 2017;33(7):718–722.
   Web of Science ®Google Scholar
• Deriaz D, Guessous I, Vollenweider P, et al. Estimated 24-h urinary sodium and sodium-to-potassium ratio are predictors of kidney function decline in a population-based study. J Hypertens. 2019;37(9):1853–1860.
   Web of Science ®Google Scholar
• Suarez-Lozano I, Fajardo JM, Garrido M, et al. Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort). Aids. 2002;16(18):2496–2499.
   Web of Science ®Google Scholar